The present invention relates to stirred tank containers, and related methods.
The general process for the manufacture of biomolecules, such as proteins, particularly recombinant proteins, typically involves two main steps: (1) the expression of the protein in a host cell, followed by (2) the purification of the protein. The first step involves growing the desired host cell in a bioreactor to effect the expression of the protein. Some examples of cell lines used for this purpose include Chinese hamster ovary (CHO) cells, myeloma (NSO) bacterial cells such as e-coli and insect cells. Once the protein is expressed at the desired levels, the protein is removed from the host cell and harvested. Suspended particulates, such as cells, cell fragments, lipids and other insoluble matter are typically removed from the protein-containing fluid by filtration or centrifugation, resulting in a clarified fluid containing the protein of interest in solution as well as other soluble impurities.
The second step involves the purification of the harvested protein to remove impurities which are inherent to the process. Examples of impurities include host cell proteins (HCP, proteins other than the desired or targeted protein), nucleic acids, endotoxins, viruses, protein variants and protein aggregates. This purification typically involves several chromatography steps, which can include affinity chromatography, ion exchange, hydrophobic interaction, etc. on solid matrices such as porous agarose, polymeric or glass or by membrane based adsorbers.
One example of a chromatography process train for the purification of proteins involves protein-A affinity, followed by cation exchange, followed by anion exchange. The protein-A column captures the protein of interest or target protein by an affinity mechanism while the bulk of the impurities pass through the column to be discarded. The protein then is recovered by elution from the column. Since most of the proteins of interest have isoelectric points (PI) in the basic range (8-9) and therefore being positively charged under normal processing conditions (pH below the PI of the protein), they are bound to the cation exchange resin in the second column. Other positively charged impurities are also bound to this resin. The protein of interest is then recovered by elution from this column under conditions (pH, salt concentration) in which the protein elutes while the impurities remain bound to the resin. The anion exchange column is typically operated in a flow through mode, such that any negatively charged impurities are bound to the resin while the positively charged protein of interest is recovered in the flow through stream. This process results in a highly purified and concentrated protein solution.
Other alternative methods for purifying proteins have been investigated in recent years. One such method involves a flocculation technique. In this technique, a soluble polyelectrolyte is added to an unclarified cell culture broth to capture the suspended particulates and a portion of the soluble impurities thereby forming a flocculant, which is subsequently removed from the protein solution by filtration or centrifugation.
Alternatively, a soluble polyelectrolyte is added to clarified cell culture broth to capture the biomolecules of interest, thereby forming a flocculant, which is allowed to settle and can be subsequently isolated from the rest of the solution. The flocculant is typically washed to remove loosely adhering impurities. Afterwards, an increase in the solution's ionic strength brings about the dissociation of the target protein from the polyelectrolyte, subsequently resulting in the resolubilization of the polyelectrolyte into the protein-containing solution.
In co-pending application U.S. Ser. No. 12/004,314 filed Dec. 20, 2007, the disclosure of which is hereby incorporated by reference, a polymer, soluble under certain conditions, such as temperature, pH, salt, light or combinations thereof, is used to bind impurities while in its soluble state and is then precipitated out upon a change in condition (pH or temperature, etc.) removing the impurities with it. The biomolecule of interest is then further treated using traditional chromatography or membrane adsorbers and the like.
All of the protein purification technologies discussed above share a common theme, namely, to first remove suspended particulates in a first distinct step and then in a second step separate the biomolecules of interest from soluble impurities which are inherent to the process.
In situ product recovery with derivatized magnetic particles is one example of a protein purification technique where the biomolecules of interest can be purified directly from an un-clarified cell culture broth. In this technique, a polymer shell encapsulating a magnetic bead is functionalized with an affinity ligand that seeks out and binds the target protein. A magnetic field is then applied to collect the bead-protein complexes, leaving behind the soluble impurities and insoluble particulates.
The main drawback of this technique is that it requires appreciable capital investments in design, construction and validation of high-gradient magnetic separators. Also, the technique does not lend itself to disposable applications, which are poised to become the norm for protein purification in the Bioprocess industry.
In co-pending application filed Dec. 16, 2008 under Ser. No. 12/316,708, entitled “Purification of Proteins” by Moya, Wilson, et al., the disclosure of which is hereby incorporated by reference, there is disclosed a polymer such as a soluble polymer capable of substantially irreversibly binding to insoluble particulates and a subset of soluble impurities and also capable of reversibly binding to one or more desired biomolecules in an unclarified biological material containing stream and the methods of using such a material to purify one or more desired biomolecules from such a stream without the need for prior clarification. More specifically, this co-pending application discloses a stimuli responsive polymer such as a selectively soluble polymer capable of selectively and reversibly binding to one or more desired biomolecules in an unclarified biological material containing stream and the methods of using such a polymer to purify one or more desired biomolecules from such a complex mixture of materials including the biomolecule(s) of interest and various impurities such as other proteins (host cell proteins), DNA, virus, whole cells, cellular debris and the like without the need for prior clarification of the stream.
The polymer is soluble under a certain set of process conditions such as one or more of pH, salt concentration, temperature, light, or electrical field, and is able to interact and complex with insoluble impurities (cells, debris, etc.) and a fraction of the soluble impurities, and is rendered insoluble and precipitates out of solution upon a change in conditions (temperature, salt concentration, light, electrical field, or pH), e.g. a stimuli responsive polymer. Only when precipitated out of solution, the polymer is capable of reversibly binding to one or more desired biomolecules within the stream (protein, polypeptide, etc.) in an unclarified cell broth. The precipitate can then be removed from the stream, such as by being filtered out from the remainder of the stream and the desired biomolecule is recovered such as by selective elution from the precipitate.
The removal of the precipitate, however, can be problematic, as it is typically in the form a large mass of sludge.
It would be desirable to provide an apparatus and method for the efficient purification of samples, particularly those containing biomolecules, preferably within a single, integral, apparatus that reduces or eliminates one or more process steps that can result in contamination or material loss.
The problems of the prior art have been overcome by the embodiments disclosed herein, which include a container or housing for sample preparation or processing, such as biomass culturing or processing, and optionally sample purification. In certain embodiments, the container or housing is a mixer. In certain embodiments, the container or housing is a reactor. In certain embodiments, the reactor is a bioreactor, which can be disposable or reusable, that includes a stirred cell device that can simulate a tangential flow filter to reduce or eliminate clogging that can be caused by the solids generated. In certain embodiments, the solids comprise a precipitate or floc, such as one that includes a polymer that binds the biomolecule(s) of interest, and impurities such as cells and cell components. In certain embodiments, the stirred cell component includes one or more membranes for purification, such as during recovery (e.g., by elution) of the biomolecule(s) of interest. In certain embodiments, the biomolecules are proteins, polypeptides or antibodies. In certain embodiments, the container has two compartments. In certain embodiments the container has two compartments each of which has a membrane with it. In certain embodiments, the container has two compartments, the first having a membrane, the second being in fluid communication with a filter device downstream of the second compartment outlet.
In its method aspects, embodiments disclosed herein include purification and isolation of biomolecules of interest derived from cell culture fluids. In certain embodiments, the methods include carrying out sample preparation or processing in a container or housing, such as culturing a biomass; generating solids such as by precipitating or flocculating a biomolecule of interest from the cultured broth; preventing the solids from settling in the container by agitation; and purification, such as by binding and eluting the biomolecule of interest and filtering the same. In certain embodiments, the sample processing involves expressing a protein of interest. In certain embodiments, the solids comprise a precipitate that includes a polymer bound to the protein of interest, and the purification involves binding and elution and one or more filtration steps. In certain embodiments, the solids comprise a precipitate that includes a polyelectrolyte bound to the protein of interest, and the purification involves binding and elution and one or more filtration steps. In certain embodiments, the polymer is bound to the impurities (cells, cell debris, etc.) and the biomolecule remains in the supernatant. The precipitation step may replace conventional chromatographic separations, may be used as a direct capture step to isolate the protein of interest from the cell culture broth, or may simply be an intermediate purification step. In certain embodiments, affinity or ion exchange beads or beads having any ligand or functionality capable of purifying the biomolecule may be used instead of a polymer to bind a biomolecule of interest. In certain embodiments, the one or more filtration steps are carried out in situ in the same apparatus as the sample processing. In certain embodiments, the eluted protein is subjected to further purification, such as by affinity and/or ion exchange chromatography.
Suitable containers or housings useful here in useful herein are not particularly limited. For purposes of illustration, reactors, and in particular, bioreactors, will be discussed in detail, which include disposable as well as reusable bioreactors. For example, solvent-resistance bioreactors having a borosilicate glass cylinder and PTFE components, such as those commercially available from Millipore Corporation, can be used. Similarly, disposable bioreactors that utilize bags, or that are formed of semi-rigid or rigid molded plastic, can be used. Such disposable bioreactors are generally pre-sterilized. Means for agitation within the bioreactor is also not particularly limited, and includes impeller-based agitation, magnetic stirrers, as well as wave-induced agitation and agitation induced by gas bubbles. Agitation is important in preventing solids from settling and plugging the one or more membranes used for purification.
The following description is in reference to a bioreactor. Those skilled in the art will appreciate that it is for illustrative purposes only, and that the embodiments disclosed herein are applicable to any container containing a liquid sample having, or ultimately forming, a sample having a relatively high solids content.
Turning now to
Depending upon the type of circulation or agitation system used, the stand 4 may also support the drive mechanism 12 (as shown) for the circulation mechanism, which typically is a stirrer or paddle assembly 14. In this particular embodiment, the drive mechanism 12 is a motor and is mounted to the top of the centered above the top 16 of the bioreactor 2 by several arms 18 (although 3 are shown alternative numbers may be used). Other features such as mounting blocks (not shown) and the like may be formed on the top 16 or support rim 8 to support the drive mechanism 12. As shown, the drive mechanism 12 has a shaft 20 that can be attached to the stirrer as explained later herein. Other stands can be used in lieu of the design described above and will work equally well.
The bioreactor body 22 (only partially shown in
The body 22 has one or more sidewalls 26 that extend downwardly from the top 16. As shown, there is one sidewall 26 of a circular or cylindrical design. Alternatively, there can be 3, 4, or more sidewalls if desired (not shown).
Preferably, the body 22 is made of a single piece of molded plastic or glass. Alternatively it may be made of two or more pieces of plastic or glass that are sealed together such as by heat, glue, or gaskets (not shown). Suitable polymers which can be used to form the top and body include but are not limited to polycarbonates, polyesters, nylons, PTFE resins and other fluoropolymers, acrylic and methacrylic resins and copolymers, polysulphones, polyethersulphones, polyarylsulphones, polystyrenes, polyetherimides, nylons, polyesters, polyethylene terephthalates (PET), polyvinyl chlorides, chlorinated polyvinyl chlorides, ABS and its alloys and blends, polyolefins, preferably polyethylenes such as linear low density polyethylene, low density polyethylene, high density polyethylene, and ultrahigh molecular weight polyethylene and copolymers thereof, polypropylene and copolymers thereof and metallocene generated polyolefins. Preferred polymers are polyolefins, in particular polyethylenes and their copolymers; polystyrenes; and polycarbonates. The top and body may be made of the same polymer or different polymers as desired. In reusable embodiments, the body can be made of glass, acrylic, or other materials not deleterious to the process. The body 22 also can be a disposable plastic bag, as is known in the art.
Also formed in the bioreactor 2 of this embodiment are one or more ports 30 (in this embodiment there are three types 30a-c (for a total of 5 ports) formed in the top 16 and one or more ports 32 in the body 22 (in this embodiment there are at least two different types 32a-b for a total of seven ports overall). The top 16 and body 22 may have multiple ports of similar and/or of different styles to provide one with the number of ports, of the desired type, in the desired locations throughout the bioreactor 2. These ports 30, 32 or at least a portion of them are formed as part of the top 16 and/or body 22. They may be formed with threads that mate to sealable covers such as closed caps, gasketed caps with a throughbore within the gasket, or various Luer fittings. Alternatively, one or more of the ports can be made in the plastic top 16 and/or body 22 by drilling or burning a hole and then mounting (such as by heat bonding or adhesives) a port in place through or around the hole. Many different port styles and sizes can be accommodated.
Ports 30a may be used for liquid or gas entrance or exit or for probes such as pH probes, thermometers or thermocouples or the like. Ports 30b may be used for similar purposes. Port 30c is for the stirrer shaft described in further detail herein. Alternatively, if the bioreactor is an airlift design and doesn't use a stirrer rod, the port 30c may be used to house the airline to the sparger at or near the bottom of the body or for any other desired purpose. Ports 32a may be used for sampling of the liquid or for probes such as pH, temperature, dissolved oxygen, lactose level, etc. as are common on such bioreactors. Ports 32a while shown as being formed on the sidewall 26 may also be formed in the bottom if desired as shown in
Preferably, one or more ports 32 of the body are formed in a location that is below the normal liquid/gas interface level of the bioreactor.
If desired, one or more of the ports 32a or b in
In accordance with certain embodiments, the bioreactor is a cylindrical tube, and is removably and sealingly affixed to a base in order to provide a stirred cell assembly. For example, in the embodiment shown, shaft 40 is extended below paddle 42 via a short shaft portion 40′, and an additional paddle or the like 42′ is added (
Turning to
The surface 101 of the base 100 supports one or more membranes 110 (
Depending on the mixture, polymer and the nature of biomolecule, the filter may be hydrophilic or hydrophobic. Preferred filters are hydrophilic and are low in protein binding.
The filter, be it membrane or otherwise, may be symmetric in pore size throughout its depth such as DURAPORE® PVDF membranes available from Millipore Corporation of Billerica Mass., or it may be asymmetric in pore size through its thickness as with MILLIPORE EXPRESS® and MILLIPORE EXPRESS® PLUS or SH PES membranes available from Millipore Corporation of Billerica Mass. It may contain a prefilter layer if desired, either as a separate upstream layer or as an integral upstream portion of the membrane itself.
Depending on the size of the particles generated, there may be instances in which the membrane is an ultrafiltration membrane. For example, in cases in which the particle size is small compared to the pore size of a microporous membrane, then a membrane with smaller pores (in the UF range) would be more appropriate to avoid plugging. Suitable ultrafiltration membranes include regenerated cellulose and polyethersulfone membranes, including those with a pore size larger than 0.2 microns, e.g., generally those with pore sizes of 0.45, 0.65, 1.0, 2.0 microns or larger. Optionally a porous support (not shown) can be placed between the surface 101 of the base and the membrane(s) 110. The membrane(s) (and support if present) are sealed against the base such as with an O-ring 106, which in turn can be held in place by a support ring 107, such as an acrylic ring. Where more than one membrane 110 is used, they can be assembled in a stacked relationship. Where more than one membrane is used, each membrane need not be of the same performance characteristics (e.g, pore size, flux, capacity, surface chemistry, etc). For example, the upper membrane against the paddle 42′ may be of a larger pore size than the lower membrane(s) and/or it may be of a different material than the lower membrane(s).
The bioreactor body 22, such as a cylindrical tube, is placed in sealing relationship with the base 100, as shown in
In certain embodiments, where additional purification is desired, a further filter base can be added to the assembly, as shown in
The housing 22′ includes an inlet port 50 that can be placed in fluid communication with the outlet 32b of the base 100, such as with suitable tubing 51 (
An alternative embodiment is to have the outlet of the second housing 22′ in fluid communication with the outlet 32 of the base 100 but to have the second housing contain no filter or membrane. Instead the outlet port 32′ is in fluid communication via a tube or other conduit (not shown) with a self contained filter device (not shown) such as a Millex® filter or an Optiscale® or Opticap® filter that then sterile filters the biomolecule of interest. The outlet of this filter device is then connected to a suitable point of use, such as a further purification step (e.g., a chromatography process train).
Suitable valving and sensing equipment can be associated with one or more of the various inlets and outlets to detect or measure and control flow or any other characteristic, such as the presence of the biomolecule or the presence of impurities, as appropriate or desired. For example, during the cell culture phase, the outlet 32b of the base 100 is closed so that the fluid remains in the body 22 when the gas is applied through port 32a or 30a.
In certain embodiments where a polymer is added to a cell culture broth to selectively and releasably bind a biomolecule of interest, suitable polymers include poly(N-vinyl caprolactam), poly(N-acryloylpiperidine), poly(N-vinylisobutyramide), poly(N-substituted acrylamide) including [poly(N-isopropylacrylamide), poly(N,N′-diethylacrylamide), and poly(N-acryloyl-N-alkylpiperazine)], Hydroxyalkylcellulose, copolymers of acrylic acid and methacrylic acid, polymers and copolymers of 2 or 4-vinylpyridine and chitosan with either a ligand or functional group attached to it.
Suitable biomolecules of interest include proteins and antibodies. Suitable antibodies include antibody selected from the group consisting of a recombinant antibody, a recombinant monoclonal antibody, a polyclonal antibody, a humanized antibody and an antibody fragment.
In operation, the sterile device is placed within the stand and the various connections for air, liquid, probes, sampling, etc. are attached to the device at the appropriate ports. The device is filled with media to a desired level forming a liquid/air interface somewhere below where the top 16 is attached to the body 22 to leave a head space of gas as is common in such devices. At least one port 32 is below the level of the interface.
The media is then seeded with the organism to be grown, be it plant, animal cell (CHO or NSO cells for instance) virus, yeast, mold or bacteria (such as E. coli) and the liquid is circulated or agitated and air/gases and liquids moved into or out of the device in a manner to effectively grow the culture inside.
A polymer soluble under a certain set of process conditions is added, and is rendered insoluble and precipitates out of solution upon a change in conditions (e.g., temperature, salt concentration, light, electrical field, or pH). Alternatively, affinity or ion exchange beads or beads having any ligand or functionality capable of purifying the biomolecule can be added to bind to the biomolecule of interest or to the soluble impurities. Agitation is continued to inhibit the solids from settling, and the solid, which in this embodiment includes the precipitate that contains the polymer, impurities such as cells and cell debris, host cell proteins, DNA and the like and the desired biomolecule, can be washed one or more times (such as with a suitable buffer) to ensure that any impurities in the liquid or entrapped in or on the polymer have been removed. The wash step(s) can be carried out by filtration through the one or more membranes in the base 100, with supernatant being sent to waste via port 32b.
The biomolecule of interest then can be recovered, such as by selective elution of the target biomolecule from the precipitate (or beads) such as by altering the ionic strength and/or pH conditions of the solution while the impurities, including soluble and insoluble material, remain complexed with the precipitated polymer. Recovery is carried out preferably along with a sterilizing filtration step, by causing the filtration base 100′ to be in fluid communication with the base 100, such as by connecting the outlet of the base 100 to the inlet 50 of the body 22′. Accordingly, permeate from the outlet of the base 100 enters the body 22′, wets the membrane 110′, and filtration through the membrane 110′ proceeds. The purified biomolecule of interest is then recovered in the elution pool via the outlet port 32b′ of base 100′. The precipitated polymer-impurity complex (or the affinity beads) may be discarded. The driving force for filtration may be pressure or vacuum.
This application is a divisional of U.S. patent application Ser. No. 12/633,141 filed Dec. 8, 2009, which claims priority of Provisional Application Ser. No. 61/201,865 filed Dec. 16, 2008, the disclosures of which are hereby incorporated by reference.
Number | Name | Date | Kind |
---|---|---|---|
2923669 | Poitras | Feb 1960 | A |
3211645 | Ferrari | Oct 1965 | A |
3556302 | Agranant | Jan 1971 | A |
3565973 | Michaels | Feb 1971 | A |
3632507 | Witt | Jan 1972 | A |
3702806 | Oliva | Nov 1972 | A |
3737377 | Sternberg | Jun 1973 | A |
3859212 | Smalley et al. | Jan 1975 | A |
3968037 | Morgan et al. | Jul 1976 | A |
4045377 | Pearson | Aug 1977 | A |
4055469 | Snoke et al. | Oct 1977 | A |
4200695 | Chong et al. | Apr 1980 | A |
4215198 | Gordon | Jul 1980 | A |
4305829 | Kelsey et al. | Dec 1981 | A |
4317726 | Shepel | Mar 1982 | A |
4359537 | Chong | Nov 1982 | A |
4371674 | Hertel et al. | Feb 1983 | A |
4380590 | Chong | Apr 1983 | A |
4382028 | Paget | May 1983 | A |
4450078 | Walker et al. | May 1984 | A |
4515893 | Kung et al. | May 1985 | A |
4528933 | Allen | Jul 1985 | A |
4536294 | Guillet et al. | Aug 1985 | A |
4676980 | Segal et al. | Jun 1987 | A |
4780409 | Monji et al. | Oct 1988 | A |
4816567 | Cabilly et al. | Mar 1989 | A |
4828701 | Cussler | May 1989 | A |
4839046 | Chandler | Jun 1989 | A |
4863613 | Johnson et al. | Sep 1989 | A |
4904385 | Wessling et al. | Feb 1990 | A |
4912032 | Hoffman et al. | Mar 1990 | A |
4925785 | Wang et al. | May 1990 | A |
4968435 | Neff et al. | Nov 1990 | A |
5003047 | Yarmush et al. | Mar 1991 | A |
5047511 | Mehrotra | Sep 1991 | A |
5091178 | Hellstrom et al. | Feb 1992 | A |
5091313 | Chang | Feb 1992 | A |
5116754 | Fraser et al. | May 1992 | A |
5139031 | Guirguis | Aug 1992 | A |
5152903 | Neff et al. | Oct 1992 | A |
5164057 | Mori et al. | Nov 1992 | A |
5171450 | Hoots | Dec 1992 | A |
5208161 | Saunders et al. | May 1993 | A |
5238545 | Yoshioka et al. | Aug 1993 | A |
5258122 | Ha et al. | Nov 1993 | A |
5324787 | Pinschmidt, Jr. et al. | Jun 1994 | A |
5340865 | Neff et al. | Aug 1994 | A |
5342581 | Sanadi | Aug 1994 | A |
5354481 | Neff et al. | Oct 1994 | A |
5354801 | O'Toole | Oct 1994 | A |
5374971 | Clapp et al. | Dec 1994 | A |
5430110 | Ahlers et al. | Jul 1995 | A |
5512480 | Sandstrom et al. | Apr 1996 | A |
5525519 | Woiszwillo | Jun 1996 | A |
5573675 | Sommese et al. | Nov 1996 | A |
5599719 | Woiszwillo et al. | Feb 1997 | A |
5622700 | Jardieu et al. | Apr 1997 | A |
5622857 | Goffe | Apr 1997 | A |
5672347 | Aggarwal et al. | Sep 1997 | A |
5684107 | Schneider et al. | Nov 1997 | A |
5693762 | Queen et al. | Dec 1997 | A |
5714338 | Wai Fei et al. | Feb 1998 | A |
5721108 | Robinson et al. | Feb 1998 | A |
5725856 | Hudziak et al. | Mar 1998 | A |
5728559 | Nilsson et al. | Mar 1998 | A |
5733507 | Zakim | Mar 1998 | A |
5736137 | Anderson et al. | Apr 1998 | A |
5739383 | Yoon et al. | Apr 1998 | A |
5770358 | Dower et al. | Jun 1998 | A |
5807489 | Farinato et al. | Sep 1998 | A |
5840804 | Carl et al. | Nov 1998 | A |
5840851 | Plomer et al. | Nov 1998 | A |
5846816 | Forth | Dec 1998 | A |
5879564 | Farinato | Mar 1999 | A |
5929214 | Peters et al. | Jul 1999 | A |
5962649 | Noda et al. | Oct 1999 | A |
5994560 | Yoon et al. | Nov 1999 | A |
5998588 | Hoffman et al. | Dec 1999 | A |
6024955 | Asano et al. | Feb 2000 | A |
6121428 | Blank et al. | Sep 2000 | A |
6127526 | Blank | Oct 2000 | A |
6133047 | Elaissari et al. | Oct 2000 | A |
6139746 | Kopf | Oct 2000 | A |
6147176 | Neff et al. | Nov 2000 | A |
6153104 | Robertson | Nov 2000 | A |
6191242 | Ryles et al. | Feb 2001 | B1 |
6197522 | Keller et al. | Mar 2001 | B1 |
6221655 | Fung et al. | Apr 2001 | B1 |
6245555 | Curtis | Jun 2001 | B1 |
6258275 | Freitag et al. | Jul 2001 | B1 |
6294622 | Barajas et al. | Sep 2001 | B1 |
6300142 | Andrewes et al. | Oct 2001 | B1 |
6307013 | Chivers | Oct 2001 | B1 |
6358730 | Kane | Mar 2002 | B1 |
6367749 | Valiulis | Apr 2002 | B2 |
6372141 | Okano et al. | Apr 2002 | B1 |
6374684 | Dority | Apr 2002 | B1 |
6420487 | Vaidya et al. | Jul 2002 | B1 |
6454950 | Tjerneld et al. | Sep 2002 | B1 |
6521341 | Elaissari et al. | Feb 2003 | B1 |
6534633 | Weidanz et al. | Mar 2003 | B1 |
6538089 | Samra et al. | Mar 2003 | B1 |
6544424 | Shevitz | Apr 2003 | B1 |
6565872 | Wu et al. | May 2003 | B2 |
6582926 | Chilkoti | Jun 2003 | B1 |
6605714 | Vaidya et al. | Aug 2003 | B2 |
6638918 | Davison et al. | Oct 2003 | B2 |
6641735 | Yoshizako et al. | Nov 2003 | B1 |
6673598 | Akers et al. | Jan 2004 | B1 |
6676840 | Tarbet et al. | Jan 2004 | B2 |
6689836 | Vaidya et al. | Feb 2004 | B2 |
6706187 | Okano et al. | Mar 2004 | B1 |
6709862 | Curtis | Mar 2004 | B2 |
6716593 | Robins et al. | Apr 2004 | B1 |
6737235 | Cros et al. | May 2004 | B1 |
6765081 | Lin et al. | Jul 2004 | B2 |
6770758 | Pan et al. | Aug 2004 | B2 |
6805793 | Yoshizako et al. | Oct 2004 | B2 |
6821515 | Cleland et al. | Nov 2004 | B1 |
6830670 | Viovy et al. | Dec 2004 | B1 |
6852819 | Ohnishi et al. | Feb 2005 | B2 |
6858694 | Ohnishi et al. | Feb 2005 | B2 |
6863437 | Ohnishi et al. | Mar 2005 | B2 |
6867268 | Vaidya et al. | Mar 2005 | B2 |
6926832 | Collins et al. | Aug 2005 | B2 |
6956077 | Akiyama et al. | Oct 2005 | B1 |
6967085 | Hughes et al. | Nov 2005 | B1 |
6974660 | Manias et al. | Dec 2005 | B2 |
7001953 | Chen et al. | Feb 2006 | B2 |
7011930 | Manias et al. | Mar 2006 | B2 |
7012136 | Yamanaka et al. | Mar 2006 | B2 |
7052917 | Ohnishi et al. | May 2006 | B1 |
7070696 | Weir et al. | Jul 2006 | B2 |
7083948 | Sassenfeld et al. | Aug 2006 | B1 |
7157603 | Hilbrig | Jan 2007 | B2 |
7160971 | Mallapragada et al. | Jan 2007 | B2 |
7169908 | Lester et al. | Jan 2007 | B2 |
7195925 | Ohnishi et al. | Mar 2007 | B2 |
7300545 | Ohara et al. | Nov 2007 | B2 |
7355020 | Yamanaka et al. | Apr 2008 | B2 |
7364859 | Chilkoti | Apr 2008 | B2 |
7377686 | Hubbard | May 2008 | B2 |
7393698 | Furukawa et al. | Jul 2008 | B2 |
7422724 | Manginell et al. | Sep 2008 | B1 |
7429458 | Chilkoti | Sep 2008 | B2 |
7442515 | Ratner et al. | Oct 2008 | B2 |
7514007 | Chen et al. | Apr 2009 | B2 |
7541167 | Dave et al. | Jun 2009 | B2 |
7547747 | Hashimoto et al. | Jun 2009 | B2 |
7553658 | Kepka et al. | Jun 2009 | B2 |
7556835 | Hultin et al. | Jul 2009 | B2 |
7625764 | Stayton et al. | Dec 2009 | B2 |
7632656 | Kanazawa et al. | Dec 2009 | B2 |
7695905 | Furukawa et al. | Apr 2010 | B2 |
7718193 | Stayton et al. | May 2010 | B2 |
7767399 | Murphy et al. | Aug 2010 | B2 |
7981688 | Stayton et al. | Jul 2011 | B2 |
8093026 | Elaissari et al. | Jan 2012 | B2 |
8110351 | Bosnes | Feb 2012 | B2 |
8133457 | Ribault et al. | Mar 2012 | B2 |
8137559 | Katzke et al. | Mar 2012 | B2 |
8163886 | Moya | Apr 2012 | B2 |
8241591 | Ribault et al. | Aug 2012 | B2 |
8263343 | Hallgren et al. | Sep 2012 | B2 |
8313902 | Furukawa et al. | Nov 2012 | B2 |
8362217 | Moya | Jan 2013 | B2 |
8499576 | Meijer | Aug 2013 | B2 |
8507283 | Stayton et al. | Aug 2013 | B2 |
8569464 | Moya et al. | Oct 2013 | B2 |
8691918 | Jaber et al. | Apr 2014 | B2 |
8877477 | Woonton et al. | Nov 2014 | B2 |
8915374 | Franks et al. | Dec 2014 | B2 |
8999702 | Kelly, Jr. et al. | Apr 2015 | B2 |
9080933 | Stayton et al. | Jul 2015 | B2 |
9090930 | Ribault et al. | Jul 2015 | B2 |
9174860 | Franks et al. | Nov 2015 | B2 |
9217048 | Jaber et al. | Dec 2015 | B2 |
9376464 | Moya et al. | Jun 2016 | B2 |
9410181 | Ribault et al. | Aug 2016 | B2 |
20010018513 | Baker | Aug 2001 | A1 |
20020058786 | Chivers | May 2002 | A1 |
20020098567 | Vaidya et al. | Jul 2002 | A1 |
20030059840 | Chilkoti | Mar 2003 | A1 |
20030085228 | Oakes | May 2003 | A1 |
20030186293 | Ohnishi et al. | Oct 2003 | A1 |
20040009473 | Pease | Jan 2004 | A1 |
20040010163 | Hilbrig | Jan 2004 | A1 |
20040029143 | Van Ness et al. | Feb 2004 | A1 |
20040039177 | Yamanaka et al. | Feb 2004 | A1 |
20040058436 | Zhang et al. | Mar 2004 | A1 |
20040062140 | Cadogan et al. | Apr 2004 | A1 |
20040134846 | Akiyama et al. | Jul 2004 | A1 |
20040185437 | Hermet et al. | Sep 2004 | A1 |
20040219628 | Tashiro et al. | Nov 2004 | A1 |
20040248774 | Tayot | Dec 2004 | A1 |
20050016620 | Proulx et al. | Jan 2005 | A1 |
20050063259 | Isshiki et al. | Mar 2005 | A1 |
20050158782 | Furukawa et al. | Jul 2005 | A1 |
20050158851 | Furey et al. | Jul 2005 | A1 |
20050175702 | Muller-Schulte | Aug 2005 | A1 |
20050224415 | Akiyama et al. | Oct 2005 | A1 |
20050238620 | Gomer et al. | Oct 2005 | A1 |
20050272146 | Hodge et al. | Dec 2005 | A1 |
20050282169 | Turner et al. | Dec 2005 | A1 |
20060118471 | Vidalinc | Jun 2006 | A1 |
20060121519 | Patchornik | Jun 2006 | A1 |
20060162882 | O'Hara et al. | Jul 2006 | A1 |
20060189795 | Van Alstine et al. | Aug 2006 | A1 |
20060251610 | Nakahama | Nov 2006 | A1 |
20060257993 | McDevitt et al. | Nov 2006 | A1 |
20060270036 | Goodwin et al. | Nov 2006 | A1 |
20060281158 | Felder et al. | Dec 2006 | A1 |
20070148437 | Muller-Schulte | Jun 2007 | A1 |
20070193954 | Busson | Aug 2007 | A1 |
20070224241 | Stayton et al. | Sep 2007 | A1 |
20070249737 | Miller et al. | Oct 2007 | A1 |
20070298451 | Ribault et al. | Dec 2007 | A1 |
20080032396 | Chokshi | Feb 2008 | A1 |
20080131957 | Ryan et al. | Jun 2008 | A1 |
20080160559 | Carre et al. | Jul 2008 | A1 |
20080193981 | Fahrner et al. | Aug 2008 | A1 |
20080220531 | Stayton et al. | Sep 2008 | A1 |
20080254500 | Tashiro et al. | Oct 2008 | A1 |
20080255027 | Moya et al. | Oct 2008 | A1 |
20080284163 | Proulx et al. | Nov 2008 | A1 |
20080293118 | Furukawa et al. | Nov 2008 | A1 |
20080293926 | Hallgren et al. | Nov 2008 | A1 |
20090001025 | Takahashi et al. | Jan 2009 | A1 |
20090036651 | Moya | Feb 2009 | A1 |
20090050566 | Kozlov et al. | Feb 2009 | A1 |
20090130704 | Gyure | May 2009 | A1 |
20090148961 | Luchini et al. | Jun 2009 | A1 |
20090155201 | Mandeville, III et al. | Jun 2009 | A1 |
20090181450 | Ribault et al. | Jul 2009 | A1 |
20090182120 | Utermohlen et al. | Jul 2009 | A1 |
20090232737 | Moya et al. | Sep 2009 | A1 |
20090233327 | Lau et al. | Sep 2009 | A1 |
20090311776 | Kelly, Jr. et al. | Dec 2009 | A1 |
20100012589 | Ribault et al. | Jan 2010 | A1 |
20100190963 | Moya et al. | Jul 2010 | A1 |
20100193148 | McKay et al. | Aug 2010 | A1 |
20100200507 | Kozlov et al. | Aug 2010 | A1 |
20100209987 | Elaissari et al. | Aug 2010 | A1 |
20100215749 | Stayton et al. | Aug 2010 | A1 |
20100267933 | Wilson | Oct 2010 | A1 |
20100282425 | Karppi et al. | Nov 2010 | A1 |
20110020327 | Moya et al. | Jan 2011 | A1 |
20110045081 | Steitz et al. | Feb 2011 | A1 |
20110065900 | Johansson et al. | Mar 2011 | A1 |
20110174735 | Ribault et al. | Jul 2011 | A1 |
20110257435 | Favero et al. | Oct 2011 | A1 |
20110313066 | Jaber et al. | Dec 2011 | A1 |
20120070836 | Zillmann et al. | Mar 2012 | A1 |
20120077249 | Ramaswamy et al. | Mar 2012 | A1 |
20120283419 | Thiyagarajan et al. | Nov 2012 | A1 |
20130123476 | Moya | May 2013 | A1 |
20130137860 | Moya et al. | May 2013 | A1 |
20130317204 | Moya et al. | Nov 2013 | A1 |
20140171594 | Jaber et al. | Jun 2014 | A1 |
20140263011 | Thiyagarajan et al. | Sep 2014 | A1 |
20150018440 | Woonton et al. | Jan 2015 | A1 |
20150133636 | Xenopoulos et al. | May 2015 | A1 |
20150218208 | Koguma et al. | Aug 2015 | A1 |
20150239956 | Koguma et al. | Aug 2015 | A1 |
20150268236 | Stayton et al. | Sep 2015 | A1 |
20150291656 | Hobel et al. | Oct 2015 | A1 |
Number | Date | Country |
---|---|---|
0162034 | Nov 1990 | EP |
0162034 | Nov 1990 | EP |
0534016 | Mar 1993 | EP |
0420937 | Nov 1994 | EP |
0922715 | Jun 1999 | EP |
0851768 | Apr 2002 | EP |
1312643 | May 2005 | EP |
1532243 | May 2005 | EP |
1201667 | Sep 2005 | EP |
1832341 | Sep 2007 | EP |
1923461 | May 2008 | EP |
1312671 | Apr 2009 | EP |
1969292 | Mar 2011 | EP |
2344517 | Jun 2014 | EP |
1928580 | Aug 2014 | EP |
2297926 | Aug 1996 | GB |
2305936 | Apr 1997 | GB |
5-95778 | Apr 1993 | JP |
6-38732 | Feb 1994 | JP |
6-116169 | Apr 1994 | JP |
6-141890 | May 1994 | JP |
9-12598 | Jan 1997 | JP |
11-505714 | May 1999 | JP |
2000-500733 | Jan 2000 | JP |
2000-86729 | Mar 2000 | JP |
2000-507927 | Jun 2000 | JP |
2001-517632 | Oct 2001 | JP |
2002-538430 | Nov 2002 | JP |
2003-114175 | Apr 2003 | JP |
2003-153684 | May 2003 | JP |
2006-284604 | Oct 2006 | JP |
2007-32559 | Feb 2007 | JP |
2008-519277 | Jun 2008 | JP |
5612761 | Oct 2014 | JP |
10-2009-0113264 | Oct 2009 | KR |
10-1551295 | Sep 2015 | KR |
9100360 | Jan 1991 | WO |
9200373 | Jan 1992 | WO |
9220373 | Nov 1992 | WO |
9304173 | Mar 1993 | WO |
9308829 | May 1993 | WO |
9314110 | Jul 1993 | WO |
9316185 | Aug 1993 | WO |
9415951 | Jul 1994 | WO |
9506249 | Mar 1995 | WO |
9519181 | Jul 1995 | WO |
9523865 | Sep 1995 | WO |
9602577 | Feb 1996 | WO |
9627011 | Sep 1996 | WO |
9630046 | Oct 1996 | WO |
9637600 | Nov 1996 | WO |
9640210 | Dec 1996 | WO |
9726912 | Jul 1997 | WO |
9806248 | Feb 1998 | WO |
9823761 | Jun 1998 | WO |
9833162 | Jul 1998 | WO |
9845331 | Oct 1998 | WO |
9851793 | Nov 1998 | WO |
9901556 | Jan 1999 | WO |
9915186 | Apr 1999 | WO |
9935500 | Jul 1999 | WO |
0012618 | Mar 2000 | WO |
0046262 | Aug 2000 | WO |
0067901 | Nov 2000 | WO |
0075348 | Dec 2000 | WO |
0107548 | Feb 2001 | WO |
0140309 | Jun 2001 | WO |
0152612 | Jul 2001 | WO |
03101486 | Dec 2003 | WO |
2004056312 | Jul 2004 | WO |
2004092393 | Oct 2004 | WO |
2005010141 | Feb 2005 | WO |
2005021129 | Mar 2005 | WO |
2005108546 | Nov 2005 | WO |
2005118771 | Dec 2005 | WO |
2006085321 | Aug 2006 | WO |
2006138143 | Dec 2006 | WO |
2007002690 | Jan 2007 | WO |
2007038523 | Apr 2007 | WO |
2007073311 | Jun 2007 | WO |
2007104456 | Sep 2007 | WO |
2007148230 | Dec 2007 | WO |
2008004988 | Jan 2008 | WO |
2008079280 | Jul 2008 | WO |
2008079302 | Jul 2008 | WO |
2008091740 | Jul 2008 | WO |
2008097154 | Aug 2008 | WO |
2008109667 | Sep 2008 | WO |
2009089570 | Jul 2009 | WO |
2009141664 | Nov 2009 | WO |
2009158606 | Dec 2009 | WO |
2010082894 | Jul 2010 | WO |
2014090838 | Jun 2014 | WO |
2014123484 | Aug 2014 | WO |
2014123485 | Aug 2014 | WO |
2014133458 | Sep 2014 | WO |
2014133459 | Sep 2014 | WO |
2014133460 | Sep 2014 | WO |
Entry |
---|
Agarwal (1996) Prot Exp and Pur 7: 294-298. |
Office Action mailed Jan. 31, 2013 in corresponding U.S. Appl. No. 12/633,141. |
Office Action mailed Mar. 15, 2013 in co-pending U.S. Appl. No. 13/108,576. |
Final Rejection mailed Jun. 25, 2013 in corresponding U.S. Appl. No. 12/633,141. |
International Preliminary Report on Patentability mailed Jun. 30, 2011 in co-pending PCT application No. PCT/US2009/006363. |
International Preliminary Report on Patentability mailed Nov. 29, 2012 in co-pending PCT application No. PCT/US2011/036648. |
International Preliminary Report on Patentability mailed Dec. 20, 2012 in co-pending PCT application No. PCT/US2011/039595. |
Merriam Webster Dictionary, accessed May 14, 2013 at http://www.merriam-webster.com/dictionary/associated, Definition of the word “associate . . . ” 6 pages. |
Restriction mailed May 9, 2013 in co-pending U.S. Appl. No. 13/747,495. |
Office Action mailed Apr. 30, 2013 in co-pending U.S. Appl. No. 13/155,912. |
Office Action mailed Apr. 15, 2013 in co-pending U.S. Appl. No. 13/108,576. |
Notice of Allowance mailed Aug. 21, 2013 in co-pending U.S. Appl. No. 12/316,708. |
Final Rejection mailed Aug. 19, 2013 in co-pending U.S. Appl. No. 12/387,688. |
Biotechnol. Appl. Biochem. (1999), vol. 30, pp. 235-244, “Expression system for foreign genes using the fission yeast Schizosaccharomyces pombe”, Giga-Hama, et al. |
European Search Report mailed Jul. 9, 2013 in corresponding European Patent Application No. EP 09835506.8. |
Office Action mailed Nov. 25, 2013 in co-pending U.S. Appl. No. 13/747,495. |
Office Action mailed Dec. 9, 2013 in co-pending U.S. Appl. No. 13/955,024. |
Notice of Allowance mailed Nov. 22, 2013 in co-pending U.S. Appl. No. 13/108,576. |
Office Action—Restriction—mailed Oct. 28, 2013 in co-pending U.S. Appl. No. 13/955,024. |
Final Rejection mailed Oct. 22, 2013 in co-pending U.S. Appl. No. 13/108,576. |
Protein Expression and Purification, vol. 7, Article No. 0042, 1996, pp. 294-298, “Sequential Precipitation with Reversibly Soluble Insoluble Polymers as a Bioseparation Strategy: Purification of B-Glucosidase from Trichoderma longibrachiatum”, Agarwal, et al. |
Journal of Chromatography B, vol. 761, No. 2, 2001, pp. 247-254, “New antibody purification procedure using a thermally responsive poly(N-isopropylacrylamide)-dextran derivative conjugate”, Anastase-Ravion, et al. |
Cell, vol. 61, No. 7, Jun. 1990, pp. 1303-1313, “CD44 is the Principal Cell Surface Receptor for Hyaluronate”, Aruffo, et al. |
Process Technology Proceedings, vol. 4, Proceedings of the International Symposium on Flocculation in Biotechnology and Separations Systems, San Francisco, California, Jul. 28-Aug. 1, 1986, pp. 429 & 441, “Flocculation in Biotechnology and Separation Systems”, Attia. |
Journal of Chromatography A, vol. 1119, 2006, pp. 58-65, “Aqueous chromatography system using pH- and temperature-responsive stationary phase with ion-exchange groups”, Ayano, et al. |
Science, vol. 229, Jul. 1985, pp. 81-83, “Preparation of Bispecific Antibodies by Chemical Recombination of Monoclonal Immunoglobulin G1 Fragments”, Brennan, et al. |
Monoclonal Antibody Production Techniques and Application, pp. 51-63 (Marcel Dekker, Inc., New York 1987), “Mouse-Human Myeloma Partners for the Production of Heterohybridomas”, Brodeur, et al. |
The Year in Immunology, vol. 7, 1993, pp. 33-40, “Designer Mice: The Production of Human Antibody Repertoires in Transgenic Animals”, Bruggemann, et al. |
Bio/Technology, Nature Publishing Group, vol. 10, Feb. 1992, pp. 163-167, “High Level Escherichia coli Expression and Production of a Bivalent Humanized Antibody Fragment”, Carter, et al. |
Macromolecular Bioscience, vol. 5, No. 5, 2005, pp. 373-378, “Highly Branched Stimuli Responsive Poly[(N-isopropylacrylamide)-co-(1,2-propandiol-3-methacrylate)]s with Protein Binding Functionality”, Carter, et al. |
Proc. Natl. Acad. Sci. USA, vol. 89, May 1992, pp. 4285-4289, “Humanization of an anti-p185HER2 antibody for human cancer therapy”, Carter, et al. |
“Technology: Temperature-responsive polymers”, document retrieved on Oct. 13, 2010, available at: http://www.cellseed.com/technology-e/index.html, 1 page, Cellseed, Inc. |
Cancer Research (Suppl.), vol. 55, Dec. 1, 1995, pp. 5852s-5856s, “Biological Activity of Two Humanized Antibodies against Two Different Breast Cancer Antigens and Comparison to Their Original Murine Forms”, Ceriani, et al. |
Macromolecular Chemistry and Physics, vol. 196, No. 4, Apr. 1995, pp. 1251-1259, “A new temperature- and pH-responsive copolymer for possible use in protein conjugation”, Chen, et al. |
Nature, vol. 373, No. 5, Jan. 1995, pp. 49-52, “Graft copolymers that exhibit temperature-induced phase transitions over a wide range of pH”, Chen, et al. |
Langmuir, vol. 21, No. 25, 2005, pp. 11673-11677, “pH-Dependence of the Properties of Hydrophobically Modified Polyvinylamine”, Chen, et al. |
Biomaterials, vol. 11, No. 9, Nov. 1990, pp. 631-633, “Polymer-protein conjugates. II. Affinity precipitation separation of human immunogammaglobulin by a poly (N-isopropylacrylamide)-protein A conjugate”, Chen, et al. |
Colloids and Surfaces B: Biointerfaces, vol. 6, 1996, pp. 37-49, “Characterization of pH-sensitive polymeric supports for selective precipitation of proteins”, Chern, et al. |
Journal of Molecular Biology, vol. 196, 1987, pp. 901-917, “Canonical Structures for the Hypervariable Regions of Immunoglobulins”, Chothia, et al. |
Arthritis & Rheumatism, vol. 39, No. 1, Jan. 1996, pp. 52-56, “Percentage of anti-CD4 monoclonal antibody-coated lymphocytes in the rheumatoid joint is associated with clinical improvement. Implications for the development of immunotherapeutic dosing regimens”, Choy, et al. |
Nature, vol. 352, Aug. 1991, pp. 624-628, “Making antibody fragments using phage display libraries”, Clackson, et al. |
Bioseparation, vol. 7, No. 4-5, Jul. 1999, pp. 231-240, “Affinity precipitation of monoclonal antibodies by nonstoichiometric polyelelectrolyte complexes”, Dainiak, et al. |
Journal of Colloid and Interface Science, vol. 179, No. 1, 1996, pp. 188-193, “Temperature-Sensitive Flocculants Based on Poly (N-isopropylacrylamide-co-diallyldimethylammonium Chloride)”, Deng, et al. |
Critical Care Medicine, vol. 23, No. 9, Sep. 1995, pp. 1461-1469, “CDP571, a humanized antibody to human tumor necrosis factor-alpha: Safety, pharmacokinetics, immune response, and influence of the antibody on cytokine concentrations in patients with septic shock”, Dhainaut, et al. |
Nature, vol. 411, May 2001, pp. 59-62, “Size-dependent control of the binding of biotinylated proteins to streptavidin using a polymer shield”, Ding, et al. |
Nature, vol. 355, Jan. 1992, pp. 258-262, “Immunization of hu-PBL-SCID mice and the rescue of human monoclonal Fab fragments through combinatorial libraries”, Duchosal, et al. |
Journal of Polymer Science, vol. XIII, No. 6, Feb. 1954, pp. 85-91, “Viscosities of Dilute Aqueous Solutions of a Partially Quaternized Poly-4-vinylpyridine at Low Gradients of Flow”, Eisenberg, et al. |
The Journal of Immunology, vol. 155, No. 2, 1995, pp. 925-937, “Engineered Anti-CD38 Monoclonal Antibodies for Immunotherapy of Multiple Myeloma”, Ellis, et al. |
Flocculation in Biotechnology and Separation Systems, 1987, pp. 441-455, “Flocculation of E. coli Bacteria With Cationic Polyelectrolytes”, Eriksson, et al. |
Flocculation in Biotechnology and Separation Systems, 1987, pp. 383-398, “Genetic Control of Flocculation of Yeast With Respect to Application in Biotechnology”, Esser, et al. |
Journal of Chromatography A, vol. 1195, 2008, pp. 94-100, “Purification of human immunoglobulin G by thermoseparating aqueous two-phase systems”, Ferriera, et al. |
Biotechnology and Bioengineering, vol. 79, No. 3, Aug. 5, 2002, pp. 271-276, “Affinity Separation Using an Fv Antibody Fragment-“Smart” Polymer Conjugate”, Fong, et al. |
Bioconjugate Chem., vol. 10, No. 5, 1999, pp. 720-725, “Thermoprecipitation of Steptavidin via Oligonucleotide-Mediated Self-Assembly with Poly (N-isopropylacrylamide)”, Fong, et al. |
Chimia 55, No. 3, 2001, pp. 196-200, “Stimulus-Responsive Polymers for Bioseparation”, Freitag, et al. |
Trends in Biotechnology, vol. 9, No. 6, Jun. 1991, pp. 191-196, “Application of reversibly soluble polymers in bioprocessing”, Fujii, et al. |
Trends in Biotechnology, vol. 17, No. 8, Aug. 1999, pp. 335-340, “‘Smart’ polymers and what they could do in biotechnology and medicine”, Galaev, et al. |
Russian Chemical Reviews, vol. 64, No. 5, 1995, pp. 471-489, “‘Smart’ polymers in biotechnology and medicine”, Galaev. |
Journal of Chromatography A, vol. 684, 1994, pp. 45-54, “Interaction of Cibacron Blue with polymers: implications for polymer-shielded dye-affinity chromatography of phosphofructokinase from baker's yeast”, Galaev, et al. |
Biotechnology and Bioengineering, vol. 71, No. 3, 2000/2001, pp. 223-234, “Use of the Avidin (Imino)biotin System as a General Approach to Affinity Precipitation”, Garret-Flaudy, et al. |
Process Biochemistry, vol. 34, No. 6-7, Sep. 1999, pp. 577-580, “Purification of Aspergillus sp xylanase by precipitation with an anionic polymer Eudragit S 100”, Gawande, et al. |
Progress in Polymer Science, vol. 29, No. 12, Dec. 2004, pp. 1173-1222, “Stimuli-responsive polymers and their bioconjugates”, Gil, et al. |
Monoclonal Antibodies: Principles and Practice, Academic Press, 1986, pp. 59-103, “3. Production of Monoclonal Antibodies”, Goding. |
The Journal of Immunology, vol. 155, No. 10, 1995, pp. 4996-5002, “Construction and Characterization of a Humanized Anti-gamma-Ig Receptor Type I (Fc gamma RI) Monoclonal Antibody”, Graziano, et al. |
The Journal of Immunology, vol. 152, No. 11, 1994, pp. 5368-5374, “Efficient Tumor Cell Lysis Mediated by a Bispecific Single Chain Antibody Expressed in Escherichia coli”, Gruber, et al. |
Bioseparation, vol. 5, 1995, pp. 339-350, “Alternative modes of precipitation of Eudragit S-100: a potential ligand carrier for affinity precipitation of protein”, Guoqiang, et al. |
Journal of Molecular Recognition, vol. 9, 1996, pp. 356-359, XP-002538983, “Affinity Precipitation of Proteins”, Gupta, et al. |
Am Inst. of Chem Engineers Journal, Jul. 2003, vol. 49, No. 7, pp. 1687-1701, “Flocculation of Biological Cells: Experiment vs. Theory”, Han, et al. |
Analyst, vol. 129, 2004, pp. 421-427, “Capturing of acidic macromolecules from biological samples using a temperature-responsive polymer modified with poly-L-lysine”, Hayashi, et al. |
Journal of Chromatography B, vol. 790, Jun. 2003, pp. 79-90, “Protein purification by affinity precipitation”, Hilbrig, et al. |
The Proceedings of the National Academy of Sciences, USA, vol. 90, No. 14, Jul. 1993, pp. 6444-6448, “‘Diabodies’: Small bivalent and bispecific antibody fragments”, Holliger, et al. |
Journal of Molecular Biology, vol. 227, No. 2, Sep. 1992, pp. 381-388, “By-passing Immunisation: Human Antibodies from Synthetic Repertoires of Germline VH Gene Segments Rearranged in vitro”, Hoogenboom, et al. |
Molecular Immunology, vol. 28, No. 9, Sep. 1991, pp. 1027-1037, “Construction and expression of antibody-tumor necrosis factor fusion proteins”, Hoogenboom, et al. |
Biotechnology and Bioengineering, vol. 60, No. 5, Dec. 1998, pp. 568-579, “Preparation of a New Thermo-Responsive Adsorbent with Maltose as a Ligand and Its Application to Affinity Precipitation”, Hoshino, et al. |
Transplantation, vol. 58, No. 3, 1994, pp. 377-380, “Administration of an anti-CD11a monoclonal antibody in recipients of kidney transplantation. A pilot study”, Hourmant, et al. |
Biotechnology Techniques, vol. 4, No. 1, 1990, pp. 55-60, “The Flocculation of Bacteria Using Cationic Synthetic Flocculants and Chitosan”, Hughes, et al. |
Bioseparation, vol. 7, No. 4-5, 1999, pp. 207-220, “Polycomplexes—potential for bioseparation”, Izumrudov, et al. |
Proc. Natl. Acad. Sci. USA, vol. 90, Mar. 1993, pp. 2551-2555, “Analysis of homozygous mutant chimeric mice: Deletion of the immunoglobulin heavy-chain joining region blocks B-cell development and antibody production”, Jakobovits, et al. |
Nature, vol. 362, Mar. 1993, pp. 255-258, “Germ-line transmission and expression of a human-derived yeast artificial chromosome”, Jakobovits, et al. |
Nature, vol. 321, May 1986, pp. 522-525, “Replacing the complementarity-determining regions in a human antibody with those from a mouse”, Jones, et al. |
Cancer Research (Suppl.), vol. 55, Dec. 1995, pp. 5908s-5910s, “Radiolabeled Anti-CD33 Monoclonal Antibody M195 for Myeloid Leukemias”, Jurcic, et al. |
Cancer Research (Suppl.), vol. 55, Dec. 1995, pp. 5899s-5907s, “Treatment of Non-Hodgkin's Lymphoma with Radiolabeled Murine, Chimeric, or Humanized LL2, an Anti-CD22 Monoclonal Antibody”, Juweid, et al. |
Biotechnology and Bioengineering, vol. 40, No. 11, Dec. 1992, pp. 1381-1387, “Purification of Recombinant Protein A by Aqueous Two-Phase Extraction Integrated with Affinity Precipitation”, Kamihira, et al. |
Anal. Chem., vol. 69, No. 5, 1997, pp. 823-830, “Temperature-Responsive Liquid Chromatography. 2. Effects of Hydrophobic Groups in N-isopropylacrylamide Copolymer-modified Silica”, Kanazawa, et al. |
Journal of Chromatography A, vol. 1106, Feb. 2006, pp. 152-158, “Temperature-responsive stationary phase utilizing a polymer of proline derivative for hydrophobic interaction chromatography using an aqueous mobile phase”, Kanazawa, et al. |
Biochemical Engineering Journal, vol. 40, No. 3, 2008, pp. 512-519, “Flocculation enhanced microfiltration of Escherichia coli lysate”, Karim, et al. |
Journal of Membrane Science, vol. 182, No. 1-2, Feb. 2001, pp. 161-172, “Flocculation to enhance microfiltration”, Kim, et al. |
Flocculation in Biotechnology and Separation Systems, 1987, pp. 429-439, “Removal of Cell and Cell Debris by Electrostatic Adsorption of Positively Charged Polymeric Particles”, Kim, et al. |
Growth Factors, vol. 7, 1992, pp. 53-64, “The Vascular Endothelial Growth Factor Proteins: Identification of Biologically Relevant Regions by Neutralizing Monoclonal Antibodies”, Kim, et al. |
The Journal of Immunology, pp. 2453-2455, Reprinted with permission from Nature, vol. 256 (5517): 495-497 (1975), “Continuous cultures of fused cells secreting antibody of predefined specificity”, Kohler, et al. |
The Journal of Immunology, vol. 148, No. 5, 1992, pp. 1547-1553, “Formation of a bispecific antibody by the use of leucine zippers”, Kostelny, et al. |
The Journal of Immunology, vol. 133, No. 6, 1984, pp. 3001-3005, “A human hybrid myeloma for production of human monoclonal antibodies”, Kozbor, et al. |
Isolation and Purification of Proteins, 2003, edited by Rajni Hatti-Kaul, et al., pp. 237-275, “Precipitation of Proteins”, Kumar, et al. |
Biotechnology and Bioengineering, vol. 59, Issue 6, 1998, pp. 695-704, “Affinity Precipitation of Amylase Inhibitor from Wheat Meal by Metal Chelate Affinity Binding Using Cu(II)-Loaded Copolymers of 1-Vinylimidazole with N-Isopropylacrylamide”, Kumar, et al. |
Prog. Polym. Sci., vol. 32, 2007, pp. 1205-1237, “Smart polymers: Physical forms and bioengineering applications”, Kumar, et al. |
Biotechnology and Bioengineering, vol. 75, No. 5, Dec. 2001, pp. 570-580, “Type-Specific Separation of Animal Cells in Aqueous Two-Phase Systems Using Antibody Conjugates with Temperature-Sensitive Polymers”, Kumar, et al. |
Am Chem Society, ACS Symposium Series, vol. 362, Chapter 7, 1988, pp. 72-101, “Scale-Up of Bioseparations for Microbial and Biochemical Technology”, Ladisch, et al. |
Nature, vol. 227, No. 5259, Aug. 1970, pp. 680-685, “Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4”, Laemmli. |
Bioseparation, vol. 7, 1999, pp. 195-205, “Carboxymethyl cellulose as a new heterobifunctional ligand carrier for affinity precipitation of proteins”, Lali, et al. |
Journal of Biotechnology, vol. 49, No. 1-3, Aug. 1996, pp. 189-199, “Evaluation of affinity precipitation and a traditional affinity chromatographic precedure for purification of soybean lectin, from extracts of soya flour”, Larsson, et al. |
Journal of Pharmaceutical Sciences, vol. 100, No. 7, Jul. 2011, pp. 2551-2562, “Assessment of Net Charge and Protein-Protein Interactions of Different Monoclonal Antibodies”, Lehermayr, et al. |
AIChE Journal, vol. 55, No. 8, Aug. 2009, pp. 2070-2080, “Effect of Molecular Weight of Poly(N-isopropylacrylamide) Temperature-Sensitive Flocculants on Dewatering”, Li, et al. |
European Journal of Immunology, vol. 26, No. 1, Jan. 1996, pp. 1-9, “Antibody-targeted superantigen therapy induces tumor-infiltrating lymphocytes, excessive cytokine production, and apoptosis in human colon carcinoma”, Litton, et al. |
The Journal of Immunology, vol. 156, No. 4, 1996, pp. 1646-1653, “In Vivo Blockade of TNF-alpha by Intravenous Infusion of a Chimeric Monoclonal TNF-alpha Antibody in Patients with Rheumatoid Arthritis. Short Term Cellular and Molecular Effects”, Lorenz, et al. |
Journal of Chromatography B, vol. 878, No. 9-10, Mar. 2010, pp. 798-806, “Using precipitation by polyamines as an alternative to chromatographic separation in antibody purification processes”, MA, et al. |
Innovative Food Science and Emerging Technologies, 2007, pp. 1-11, “Novel chromatographic separation—The potential of smart polymers”, Maharjan, et al. |
Analytical Chemistry, vol. 75, No. 13, Jul. 2003, pp. 2943-2949, “A Smart Microfluidic Affinity Chromatography Matrix Composed of Poly(N-isopropylacrylamide)-Coated Beads”, Malmstadt, et al. |
Bioconjugate Chem., 2003, vol. 14, No. 3, pp. 575-580, “Affinity Thermoprecipitation and Recovery of Biotinylated Biomolecules via a Mutant Streptavidin-Smart Polymer Conjugate”, Malmstadt, et al. |
Journal of Molecular Biology, vol. 222 No. 3, Dec. 1991, pp. 581-597, “By-passing Immunization—Human Antibodies from V-gene Libraries Displayed on Phage”, Marks, et al. |
Bio/Technology, Nature Publishing Group, vol. 10, Jul. 1992, pp. 779-783, “By-Passing Immunization: Building High Affinity Human Antibodies by Chain Shuffling”, Marks, et al. |
Nature, vol. 348, Dec. 1990, pp. 552-554, “Phage antibodies: filamentous phage displaying antibody variable domains”, McCafferty, et al. |
Millipore Pure Science Laboratory Catalogue 1999/2000, Ultrafiltration Discs and Stirred Cells, p. 127, “Solvent-resistant Stirred Cells” and “High-Output Stirred Cells”, 3 pages. |
Nature, vol. 305, Oct. 1983, pp. 537-540, “Hybrid hybridomas and their use in immunohistochemistry”, Milstein, et al. |
Journal of Biochemical and Biophysical Methods, vol. 24, 1992, pp. 107-117, “Single-step purification of F(ab′)sub.2 fragments of mouse monoclonal antibodies (immunoglobulins G1) by hydrophobic interaction high performance liquid chromatography using TSKgel Phenyl-5PW”, Morimoto, et al. |
Proc. Natl. Acad. Sci. USA, vol. 81, Nov. 1984, pp. 6851-6855, “Chimeric human antibody molecules: Mouse antigen-binding domains with human constant region domains”, Morrison, et al. |
American Inst. of Chem. Engineers, Biotechnology Progress, V 26, No. 5, (2010), pp. 1322-1331, “Monoclonal Antibody Purification Using Cationic Polyelectrolytes: An Alternative to Column Chromatography”, Peram, et al. |
Flocculation in Biotechnology and Separation Systems, 1987, pp. 457-466, “Flocculation of Cell Debris for Improved Separation by Centrifugation”, Persson, et al. |
The Journal of Immunology, vol. 151, No. 5, Sep. 1993, pp. 2623-2632, “Humanization of an Antibody Directed Against IgE”, Presta, et al. |
Current Opinion in Structural Biology, vol. 2, No. 4, Aug. 1992, pp. 593-596, “Antibody Engineering”, Presta. |
Cancer Research (Suppl.), vol. 55, Dec. 1995, pp. 5916s-5920s, “Radioimmunotherapy for Breast Cancer Using Escalating Fractionated Doses of 131-I-labeled Chimeric L6 Antibody with Peripheral Blood Progenitor Cell Transfusions”, Richman, et al. |
Nature, vol. 332, Mar. 1988, pp. 323-327, “Reshaping human antibodies for therapy”, Riechmann, et al. |
Final Rejection mailed Dec. 28, 2012 in co-pending U.S. Appl. No. 12/387,688. |
Office Action-Restriction—mailed mailed Nov. 21, 2012 in co-pending U.S. Appl. No. 13/155,912. |
International Search Report and Written opinion dated Jan. 29, 2010 in corresponding PCT application No. PCT/US09/67097, 8 pages. |
International Preliminary Report on Patentability mailed Jun. 30, 2011 in corresponding PCT Patent Application No. PCT/US2009/067097, 7 pages. |
Extended European Search Report mailed Nov. 17, 2009 in co-pending EP Patent Application No. 09161982.5, 6 pages. |
International Search Report/Written Opinion mailed Nov. 12, 2009 in co-pending PCT Patent Application No. PCT/US2009/002787, 9 pages. |
International Preliminary Report on Patentability issued Dec. 13, 2010 in co-pending PCT Patent Application No. PCT/US2009/002787, 6 pages. |
Office Action dated Nov. 17, 2010 in co-pending U.S. Appl. No. 12/387,688. |
Final Rejection dated Apr. 21, 2011 in co-pending U.S. Appl. No. 12/387,688. |
Japanese Communication mailed Oct. 16, 2012 in corresponding Japanese patent application No. 2011-542238. |
Journal of Biotechnology, vol. 128, No. 4, Mar. 2007, pp. 813-823, “The use of chitosan as a flocculant in mammalian cell culture dramatically improves clarification throughput without adversely impacting monoclonal antibody recovery”, Riske, et al. |
Biotechnol. Prog, vol. 24, No. 3, May/Jun. 2008, pp. 488-495, “Advances in Primary Recovery: Centrifugation and Membrane Technology”, Roush, et al. |
Anal. Chem., vol. 71, No. 20, Oct. 1999, pp. 4506-4512, “Concentration of Hydrophobic Organic Compounds by Polymer-Mediated Extraction”, Saitoh, et al. |
Kona, No. 20, 2002, pp. 246-250, “Flocculation Mechanism of Suspended Particles Using the Hydrophilic/Hydrophobic Transition of a Thermosensitive Polymer”, Sakohara, et al. |
Advanced Drug Delivery Reviews, vol. 58, No. 15, 2006, pp. 1655-1670, “Thermo- and pH-responsive polymers in drug delivery”, Schmaljohann. |
The Journal of Physical Chemistry B, vol. 111, No. 29, 2007, pp. 8649-8654, “Cationic Flocculants Carrying Hydrophobic Functionalities: Applications for Solid/Liquid Separation”, Schwarz, et al. |
Biotechnology and Bioengineering, vol. 34, No. 3, 1989, pp. 387-393, “Purification of Wheat Germ Agglutinin Using Affinity Flocculation with Chitosan and a Subsequent Centrifugation or Flotation Step”, Senstad, et al. |
Macromolecules, American Chemical Society, vol. 24, No. 15, 1991, pp. 4255-4263, “Self-organization of Poly(allylamine)s Containing Hydrophobic Groups and Its Effect on the Interaction with Small Molecules. 1. Static Fluorometry”, Seo, et al. |
J. Exp. Med., vol. 175, 1992, pp. 217-225, “Development of Humanized Bispecific Antibodies Reactive with Cytotoxic Lymphocytes and Tumor Cells Overexpressing the HER2 Protooncogene”, Shalaby, et al. |
Journal of Biotechnology, vol. 49, 1996, pp. 173-178, “Flocculation of cell, cell debris and soluble protein with methacryloyloxyethyl trimethylammonium chloride-acrylonitrile copolymer”, Shan, et al. |
Cancer Research (Suppl.), vol. 55, Dec. 1995, pp. 5935s-5945s, “Evaluation of a Complementarity-Determining Region-Grafted (Humanized) Anti-Carcinoembryonic Antigen Monoclonal Antibody in Preclinical and Clinical Studies”, Sharkey, et al. |
The Journal of Immunology, vol. 151, No. 4, 1993, pp. 2296-2308, “A Humanized CD18 Antibody Can Block Function Without Cell Destruction”, Sims, et al. |
Chest, vol. 103, No. 3, Mar. 1993, pp. 932-943, “Immunologic Therapy for ARDS, Septic Shock, and Multiple-Organ Failure”, St. John, et al. |
Cell, vol. 66, No. 6, 1991, pp. 1133-1144, “The B Lymphocyte Adhesion Molecule CD22 Interacts with Leukocyte Common Antigen CD45RO on T Cells and a2-6 Sialyltransferase, CD75, on B Cells”, Stamenkovic, et al. |
The Affinity Precipitation for the Isolation of Biomolecules, No. 3862, Aug. 2007, pp. 1-130, 146 pages, Stocker-Majd, et al, submitted in two parts. |
Transplant International, vol. 4, No. 1, 1991, pp. 3-7, “Anti-LFA1 monoclonal antibody (25.3) for treatment of steroid-resistant grade III-IV acute graft-versus-host disease”, Stoppa, et al. |
Journal of Chromatography A, vol. 1114, 2006, pp. 239-249, “Temperature sensitive dopamine-imprinted (N,N-methylene-bis-acrylamide cross-linked) polymer and its potential application to the selective extraction of adrenergic drugs from urine”, Suedee, et al. |
Analytical Sciences, vol. 3, No. 6, Dec. 1987, pp. 479-488, “Ion-Association Reagents, A Review”, Toei. |
The EMBO Journal, vol. 10, No. 12, 1991, pp. 3655-3659, “Bispecific single chain molecules (Janusins) target cytotoxic lymphocytes on HIV infected cells”, Traunecker, et al. |
The Journal of Immunology, vol. 147, No. 1, Jul. 1991, pp. 60-69, “Trispecific F(ab′)3 derivatives that use cooperative signaling via the TCR/CD3 complex and CD2 to activate and redirect resting cytotoxic T cells”, Tutt, et al. |
Flocculation in Biotechnology and Separation Systems, 1987, pp. 351-368, “Aspects of Bioflocculation: An Overview”, Unz. |
Nature Biotechnology, vol. 14, 1996, pp. 309-314, “Human Antibodies with Sub-nanomolar Affinities Isolated from a Large Non-immunized Phage Display Library”, Vaughan, et al. |
Science, vol. 239, Mar. 1988, pp. 1534-1536, “Reshaping Human Antibodies: Grafting an Antilysozyme Activity”, Verhoeyen, et al. |
Nucleic Acids Research, vol. 21, No. 9, 1993, pp. 2265-2266, “Combinatorial infection and in vivo recombination: a strategy for making large phage antibody repertoires”, Waterhouse, et al. |
Biotechnology and Bioengineering, vol. 108, No. 1, Jan. 2011, pp. 50-58, “Effects of Solution Environment on Mammalian Cell Fermentation Broth Properties: Enhanced Impurity Removal and Clarification Performance”, Westoby, et al. |
Biotechnology and Bioengineering, vol. 86, No. 6, 2004, pp. 612-621, “Clearance of Minute Virus of Mice by Flocculation and Microfiltration”, Wickramasinghe, et al. |
Desalination, vol. 147, No. 1-3, 2002, pp. 25-30, “Enhanced microfiltration of yeast by flocculation”, Wickramasinghe, et al. |
Separation Science and Technology, vol. 37, No. 1, pp. 217-228, 2002, “Selective Precipitation of Water-Soluble Proteins Using Designed Polyelectrolyte”, Yu, et al. |
Protein Engineering, vol. 8, No. 10, 1995, pp. 1057-1062, “Engineering linear F(ab′)2 fragments for efficient production in Escherichia coli and enhanced antiproliferative activity”, Zapata, et al. |
Nucleic Acids Research, vol. 31, No. 13, 2003, pp. 3406-3415, “Mfold web server for nucleic acid folding and hybridization prediction”, Zuker. |
International Search Report mailed Mar. 31, 2008 in co-pending PCT application No. PCT/US2007/26040. |
International Search Report dated Apr. 24, 2008 in co-pending PCT application No. PCT/US2007/26090. |
International Search Report dated Aug. 27, 2009 in co-pending PCT application No. PCT/US2008/013736. |
International Search Report dated Feb. 18, 2010 in co-pending PCT application No. PCT/US2009/006363. |
International Search Report/Written Opinion dated Dec. 6, 2011 in co-pending PCT application No. PCT/US2011/039595. |
International Search Report dated Oct. 31, 2011 in co-pending PCT application No. PCT/US2011/036648. |
Office Action mailed Jun. 11, 2010 in co-pending U.S. Appl. No. 12/004,319. |
Final Rejection mailed Apr. 13, 2011 in co-pending U.S. Appl. No. 12/004,319. |
Office Action mailed Oct. 3, 2011 in co-pending U.S. Appl. No. 12/004,319. |
Notice of Allowance mailed May 9, 2012 in co-pending U.S. Appl. No. 12/004,319. |
Notice of Allowance mailed Aug. 15, 2012 in co-pending U.S. Appl. No. 12/004,319. |
Office Action mailed Jun. 21, 2011 in co-pending U.S. Appl. No. 12/316,708. |
Office Action mailed Feb. 29, 2012 in co-pending U.S. Appl. No. 12/316,708. |
Office Action-Restriction—mailed Feb. 7, 2012 in co-pending U.S. Appl. No. 12/448,004. |
Office Action mailed Jul. 26, 2012 in co-pending U.S. Appl. No. 12/448,004. |
Office Action-Restriction—mailed Apr. 27, 2012 in co-pending U.S. Appl. No. 12/592,744. |
Office Action Feb. 21, 2012 in co-pending U.S. Appl. No. 12/387,688. |
Final Rejection mailed Sep. 25, 2012 in co-pending U.S. Appl. No. 12/316,708. |
Notice of Allowance mailed Oct. 1, 2012 in co-pending U.S. Appl. No. 12/004,319. |
Office Action-Restriction—mailed Jul. 17, 2012 in corresponding U.S. Appl. No. 12/633,141. |
French Search Report dated Jun. 2, 2009 in co-pending French patent application No. FA 713810/FR 0854844. |
Office Action mailed Feb. 26, 2009 in co-pending U.S. Appl. No. 11/805,539. |
Office Action mailed May 26, 2009 in co-pending U.S. Appl. No. 11/805,539. |
Office Action mailed Jul. 30, 2009 in co-pending U.S. Appl. No. 11/805,539. |
Final Rejection mailed Dec. 29, 2009 in co-pending U.S. Appl. No. 11/805,539. |
Final Rejection mailed Apr. 20, 2010 in co-pending U.S. Appl. No. 11/805,539. |
Final Rejection mailed Aug. 27, 2010 in co-pending U.S. Appl. No. 11/805,539. |
Final Rejection mailed Jan. 7, 2011 in co-pending U.S. Appl. No. 11/805,539. |
Office Action mailed Apr. 21, 2011 in co-pending U.S. Appl. No. 11/805,539. |
Final Rejection mailed Oct. 18, 2011 in co-pending U.S. Appl. No. 11/805,539. |
Advisory Action mailed Nov. 25, 2011 in co-pending U.S. Appl. No. 11/805,539. |
Examiner's Answer to Appeal Brief mailed Jul. 3, 2012 in co-pending U.S. Appl. No. 11/805,539. |
Office Action mailed Nov. 1, 2011 in co-pending U.S. Appl. No. 12/383,131. |
Final Rejection mailed Apr. 13, 2012 in co-pending U.S. Appl. No. 12/383,131. |
Office Action mailed Jun. 11, 2013 in co-pending U.S. Appl. No. 12/383,131. |
Final Rejection mailed Oct. 24, 2013 in co-pending U.S. Appl. No. 12/383,131. |
Office Action mailed Feb. 4, 2014 in co-pending U.S. Appl. No. 12/383,131. |
Office Action mailed Feb. 27, 2014 in co-pending U.S. Appl. No. 12/387,688. |
Office Action mailed Apr. 3, 2014 in corresponding U.S. Appl. No. 12/633,141. |
Office Action-Restiction—mailed Sep. 30, 2014 in co-pending U.S. Appl. No. 13/732,613. |
Japanese communication, with English translation, dispatched Sep. 2, 2014 in corresponding Japanese patent application No. 2013-083213. |
Journal of the Chemical Society of Japan, No. 8, Aug. 1991, pp. 1115-1126 (English Abstract Submitted), “Structure and Hydrolysis Activity of Poly(alylamine)s having Hydrophobic Groups”, Seo, et al. |
Final Rejection mailed Jun. 23, 2014 in co-pending U.S. Appl. No. 12/383,131. |
Final Rejection mailed Aug. 8, 2014 in co-pending U.S. Appl. No. 13/747,495. |
Notice of Allowance mailed Aug. 4, 2014 in co-pending U.S. Appl. No. 13/955,024. |
Office Action mailed Jul. 29, 2014 in co-pending U.S. Appl. No. 12/387,688. |
Final Rejection mailed Aug. 14, 2014 in corresponding U.S. Appl. No. 12/633,141. |
Notice of Allowance dated Jun. 4, 2015 in co-pending U.S. Appl. No. 12/383,131. |
Final Rejection dated Jul. 27, 2015 in corresponding U.S. Appl. No. 12/633,141. |
Office Action dated Mar. 16, 2015 in co-pending U.S. Appl. No. 13/732,613. |
Office Action dated Mar. 2, 2015 in corresponding U.S. Appl. No. 12/633,141. |
Notice of Allowance dated Feb. 20, 2015 in co-pending U.S. Appl. No. 12/387,688. |
Office Action dated Dec. 19, 2014 in co-pending U.S. Appl. No. 12/383,131. |
Final rejection dated Oct. 20, 2015 in co-pending U.S. Appl. No. 13/732,613. |
Office action dated Sep. 17, 2015 in co-pending U.S. Appl. No. 13/747,495. |
Notice of Allowance dated Sep. 4, 2015 in co-pending U.S. Appl. No. 13/955,024. |
Notice of Allowance dated Nov. 6, 2015 in co-pending U.S. Appl. No. 13/955,024. |
Notice of Allowance dated May 11, 2016 in co-pending U.S. Appl. No. 11/805,539. |
Notice of Allowance dated Jun. 9, 2016 in co-pending U.S. Appl. No. 11/805,539. |
Notice of Allowance dated Feb. 10, 2016 in co-pending U.S. Appl. No. 11/805,539. |
Notice of Allowance dated Mar. 2, 2016 in co-pending U.S. Appl. No. 13/747,495. |
Final rejection dated Feb. 25, 2016 in co-pending U.S. Appl. No. 12/633,141. |
Majd, Gisela S., “The affinity precipitation for the isolation of biomolecules” Thèse EPFL, No. 3862, pp. 1-130, Aug. 2007. |
International Preliminary Report on Patentability dated Jun. 24, 2009 in co-pending PCT application No. PCT/US2007/026040. |
International Preliminary Report on Patentability dated Jun. 24, 2009 in co-pending PCT application No. PCT/US2007/026090. |
International Preliminary Report on Patentability dated Jun. 22, 2010 in co-pending PCT application No. PCT/US2008/013736. |
Japanese communication, with English translation, dated Jul. 19, 2016 in co-pending Japanese patent application No. 2015-215483. |
Notice of Allowance dated Oct. 3, 2016 in co-pending U.S. Appl. No. 13/955,024. |
Office action dated Sep. 21, 2016 in co-pending U.S. Appl. No. 12/633,141. |
Final rejection dated Jan. 27, 2017 in co-pending U.S. Appl. No. 12/633,141. |
Final rejection dated May 2, 2017 in co-pending U.S. Appl. No. 13/732,613. |
Hemstrom et al., “Hydrophilic Interaction Chromatography,” Journal of Separation Science, vol. 29, Iss. 12, pp. 1784-1821, Aug. 2006. |
Nisnevitch et al., “The Solid Phase in Affinity Chromatography: Strategies for Antibody Attachment,” Journal of Biochemical and Biophysical Methods, vol. 49, pp. 467-480, Oct 30, 2001. |
Wang, “Ion Exchange in Purification,” Separation Processes in Biotechnology, pp. 359-400, 1990. |
Advisory action dated Apr. 27, 2017 in co-pending U.S. Appl. No. 12/633,141. |
Chiang et al., “Application of Superparamagnetic Nanoparticles in Purification of Plasmid DNA from Bacterial Cells,” Journal of Chromatography B, vol. 822, pp. 54-60, Aug. 5, 2005. |
Office action dated Oct. 11, 2016 in co-pending U.S. Appl. No. 13/732,613. |
Office action dated Oct. 5, 2016 in co-pending U.S. Appl. No. 14/940,864. |
Office action dated Sep. 12, 2017 in co-pending U.S. Appl. No. 13/955,024. |
Number | Date | Country | |
---|---|---|---|
20130005950 A1 | Jan 2013 | US |
Number | Date | Country | |
---|---|---|---|
61201865 | Dec 2008 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 12633141 | Dec 2009 | US |
Child | 13610954 | US |